OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wright Discusses Immunotherapy in Bladder Cancer

January 15th 2019

Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.

Dr. Singal on the FDA Approval of Cabozantinib in HCC

January 15th 2019

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Dr. Sun Discusses the Debate Between Radiation and Chemotherapy in GEJ Cancers

January 15th 2019

Weijing Sun, MD, gastrointestinal oncologist at the University of Kansas School of Medicine, discusses the debate between the use of radiation and chemotherapy in patients with locally advanced gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

January 15th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Martin on Selinexor in Penta-Refractory Patients With Myeloma

January 15th 2019

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Dr. Patel Discusses Promise of Acalabrutinib in MCL

January 15th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

January 15th 2019

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Dr. Shields on Optimal Adjuvant Therapy for CRC

January 14th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Karmanos Cancer Institute, discusses optimal adjuvant therapy for the treatment of patients with colorectal cancer.

Dr. Wang Discusses Next Steps With Acalabrutinib in MCL

January 12th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Dr. Goy Discusses the Cost of CAR T-Cell Therapy

January 12th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Pal on the Clinical Utility of PD-L1 in mRCC

January 12th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).

Dr. Overman Discusses Progress With Immunotherapy in GI Cancer

January 12th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses progress made with immunotherapy agents in gastrointestinal (GI) cancer.

Dr. Voorhees Discusses Safety Run-in of Daratumumab in Myeloma

January 12th 2019

Peter Voorhees, MD, professor of medicine, UNC Lineberger Comprehensive Cancer Center, discusses the safety run-in of the Griffin study looking at daratumumab in myeloma.

Dr. Davis Discusses Benefits of Robotic Thoracic Surgery

January 11th 2019

J. Russell Davis, MD, clinical professor, University of Missouri-Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, discusses the benefits of robotics in thoracic surgery.

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

January 11th 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

January 11th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Dr. Wong on the Current Landscape of NSCLC

January 11th 2019

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Dr. Neelapu Discusses Efficacy of Axi-Cel in Large B-Cell Lymphoma

January 11th 2019

Sattva Neelapu, MD, professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the efficacy of axicabtagene ciloleucel in patients with large B-cell lymphoma.

Dr. Figlin on Considerations for Combining TKIs and Immunotherapy in RCC

January 10th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Dr. Kasi Discusses Treatment Approaches for mCRC

January 10th 2019

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses treatment approaches for patients with metastatic colorectal cancer.